Introgen's

(INGN) - Get Report

shares continued to rise in the premarket session Tuesday, a day after it released data showing its anticancer drug INGN-201 was shown to be safe in a study.

The company also released results of studies Tuesday showing the treatment complemented the effects of a breast-cancer treatment in a preclinical study and enhanced the immune response of mice against tumors.

On Instinet, Introgen's shares were recently up 71 cents, or 13%, to $6.30.